Rein Therapeutics Inc.
RNTXHealthcare|Biotechnology|US
$0.61
+0.00 (+0.28%)
Cash / Share
$1.34
Ownership Breakdown
76.6%
Float
86.3M
Shares Outstanding
66.1M
Float Shares
Major Holders (40)
Combined: 178.4%
Holders of 5%+ from their latest Schedule 13D/13G filing in the last two years. Percentages are as of each filing date.
| Holder | Type | % of Class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Aaron G.L. Fletcher | Individual | 9.99% | 7,797,502 | May 8, 2026 | 13D/G |
| Leslie W. Kreis | Individual | 9.99% | 7,797,502 | May 8, 2026 | 13D/G |
| Cavu Management, LP | Partnership | 9.99% | 7,797,502 | May 8, 2026 | 13D/G |
| Cavu Advisors, LLC | Other | 9.99% | 7,797,502 | May 8, 2026 | 13D/G |
| Bios Advisors GP, LLC | Other | 9.99% | 7,797,502 | May 8, 2026 | 13D/G |
| Bios Capital Management, LP | Partnership | 9.99% | 7,797,502 | May 8, 2026 | 13D/G |
| Cable Car Capital, LP | IA, PN | 6.70% | 5,195,000 | May 7, 2026 | 13D/G |
| Ma-Weaver Jacob | Individual | 6.70% | 5,195,000 | May 7, 2026 | 13D/G |
| Funicular Funds, LP | Partnership | 6.70% | 5,195,000 | May 7, 2026 | 13D/G |
| Voss Capital, LP | Partnership | 6.60% | 5,656,957 | Jul 14, 2026 | 13D/G |
| Cocke Travis W. | Individual | 6.60% | 5,656,957 | Jul 14, 2026 | 13D/G |
| Leslie Wayne Kreis, JR. | Individual | 6.20% | 3,683,429 | Aug 11, 2025 | 13D/G |
| Aaron Glenn Louis Fletcher | Individual | 6.20% | 3,683,429 | Aug 11, 2025 | 13D/G |
| Benjamin Shapiro | Individual | 6.10% | 4,750,000 | May 8, 2026 | 13D/G |
| Bios LTI Co-Invest III QP, LP | Partnership | 5.51% | 4,303,099 | May 8, 2026 | 13D/G |
| Bios LTI Co-Invest III, LP | Partnership | 5.38% | 4,198,037 | May 8, 2026 | 13D/G |
| Daniel Schneeberger | HC, IN | 5.30% | 4,500,000 | Aug 14, 2026 | 13D/G |
| ADAR1 Capital Management, LLC | IA, OO | 5.30% | 4,500,000 | Aug 14, 2026 | 13D/G |
| Lynwood Opportunities Master Fund | Other | 5.00% | 4,280,500 | Aug 14, 2026 | 13D/G |
| Ben Shapiro | Individual | 5.00% | 4,280,500 | Aug 14, 2026 | 13D/G |
| Lynwood Capital Management Inc. | Corporation | 5.00% | 4,280,500 | Aug 14, 2026 | 13D/G |
| Lytton Laurence W | Individual | 4.90% | 4,238,628 | Aug 13, 2026 | 13D/G |
| Bios Clinical Opportunity Fund, LP | Partnership | 2.96% | 2,313,797 | May 8, 2026 | 13D/G |
| Bios Equity Partners II, LP | Partnership | 2.40% | 1,874,638 | May 8, 2026 | 13D/G |
| Bios Equity Partners III, LP | Partnership | 2.24% | 1,751,288 | May 8, 2026 | 13D/G |
| Bios Equity Cof, LP | Partnership | 2.24% | 1,751,288 | May 8, 2026 | 13D/G |
| Bios Fund I, LP | Partnership | 2.06% | 1,610,565 | May 8, 2026 | 13D/G |
| Bios LTI SPV II, LP | Partnership | 1.91% | 1,487,007 | May 8, 2026 | 13D/G |
| Voss Advisors GP, LLC | Other | 1.80% | 1,500,000 | Jul 14, 2026 | 13D/G |
| Bios Fund III QP, LP | Partnership | 1.71% | 1,332,850 | May 8, 2026 | 13D/G |
| Bios Fund II QP, LP | Partnership | 1.67% | 1,302,654 | May 8, 2026 | 13D/G |
| Bios 2026 Co-Invest, LP | Partnership | 1.28% | 1,000,000 | May 8, 2026 | 13D/G |
| Bios Fund I QP, LP | Partnership | 1.21% | 941,887 | May 8, 2026 | 13D/G |
| Voss Value Master Fund, LP | Partnership | 1.20% | 1,000,000 | Jul 14, 2026 | 13D/G |
| Bios 2024 Co-Invest, LP | Partnership | 0.72% | 562,695 | May 8, 2026 | 13D/G |
| Voss Value-Oriented Special Situations Fund, LP | Partnership | 0.60% | 500,000 | Jul 14, 2026 | 13D/G |
| Bios Fund II, LP | Partnership | 0.51% | 398,767 | May 8, 2026 | 13D/G |
| Bios Fund III NT, LP | Partnership | 0.27% | 214,346 | May 8, 2026 | 13D/G |
| Bios Fund III, LP | Partnership | 0.26% | 204,092 | May 8, 2026 | 13D/G |
| Bios Fund II NT, LP | Partnership | 0.22% | 173,217 | May 8, 2026 | 13D/G |
Insider Trades (18)
Last 4 quarters: 569,793 acquired · 150,000 disposed
| Insider | Position | Date | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| VON RICKENBACH JOSEF H | director | May 27, 2026 | BUY | 4,500 | $1.07 | $4.8K | Form 4 |
| VON RICKENBACH JOSEF H | director | May 26, 2026 | BUY | 23,190 | $1.06 | $24.5K | Form 4 |
| VON RICKENBACH JOSEF H | director | May 22, 2026 | BUY | 15,950 | $1.05 | $16.7K | Form 4 |
| VON RICKENBACH JOSEF H | director | May 21, 2026 | BUY | 3,420 | $1.04 | $3.6K | Form 4 |
| WINDSOR JAMES BRIAN | director, officer: See Remarks | May 8, 2026 | AWARD | 150,000 | $1.17 | $175.5K | Form 4 |
| WINDSOR JAMES BRIAN | director, officer: See Remarks | Apr 30, 2026 | BUY | 25,000 | $1.00 | $25.0K | Form 4 |
| Voss Capital, LP | 10 percent owner | Nov 14, 2025 | BUY | 104,183 | $1.22 | $127.6K | Form 4 |
| Voss Capital, LP | 10 percent owner | Oct 27, 2025 | BUY | 92,642 | $1.37 | $126.9K | Form 4 |
| Voss Capital, LP | 10 percent owner | Oct 24, 2025 | BUY | 30,176 | $1.39 | $42.0K | Form 4 |
| Voss Capital, LP | 10 percent owner | Oct 28, 2025 | BUY | 178,392 | $1.39 | $248.0K | Form 4 |
| Voss Capital, LP | 10 percent owner | Oct 27, 2025 | BUY | 4,840 | $1.37 | $6.6K | Form 4 |
| Voss Capital, LP | 10 percent owner | Sep 24, 2025 | OTHER | 0 | — | — | Form 4 |
| Voss Capital, LP | 10 percent owner | Sep 24, 2025 | OTHER | 0 | — | — | Form 4 |
| Aivado Manuel | director | Jul 23, 2025 | AWARD | 17,500 | $1.55 | $27.1K | Form 4 |
| VON RICKENBACH JOSEF H | director | Jul 23, 2025 | AWARD | 17,500 | $1.55 | $27.1K | Form 4 |
| Musso Alan A | director | Jul 23, 2025 | AWARD | 17,500 | $1.55 | $27.1K | Form 4 |
| Fairey William | director | Jul 23, 2025 | AWARD | 17,500 | $1.55 | $27.1K | Form 4 |
| Ambros Reinhard J. | director | Jul 23, 2025 | AWARD | 17,500 | $1.55 | $27.1K | Form 4 |